Comparisons of the Effects of Solifenacin Versus Mirabegron on Autonomic System, Arterial Stiffness and Psychosomatic Distress and Clinical Outcomes: A Prospective Randomized Controlled Trial
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 入组人数
- 113
- 试验地点
- 1
- 主要终点
- Between-group difference of the effect of drug on heart rate variability
研究概览
简要总结
Background/Purpose: The overactive bladder syndrome (OAB) affects around 17 % of female population. Antimuscarinics can affect autonomic system, arterial stiffness and psychosomatic distress. However, there is no such research for the new drug- mirabegron (a β3-agonist). Thus, the aim of our study is to analyze the between-group differences in heart rate variability, cardio-ankle vascular index, ankle-brachial pressure index, psychosomatic distress, personality trait, family support and clinical outcomes between the mirabegron and the solifenacin groups.
Patients and Methods: The investigators will perform a prospective randomized controlled study to recruit 150 female OAB patients at the outpatient clinic of Department of Obstetrics and Gynecology of National Taiwan University Hospital. All OAB female patients will be asked to complete Urgency Severity Scales, Overactive Bladder Symptoms Scores questionnaires, King's Health questionnaires, UDI-6 & IIQ-7, Patient Health Questionnaire, brief symptom rating scale (BSRS), Maudsley personality inventory (MPI) and adaptability, partnership, growth, affection, and resolve (APGAR) questionnaires, Sleep and Dietary habit Questionnaire, standard 12-leads electrocardiography (ECG), 5 minutes Holter monitoring, cardio-ankle vascular index (CAVI) test, bladder diary, 20-min pad test, urodynamic studies and measurement of urinary nerve growth factors level before and after 12 weeks' mirabegron versus solifenacin treatment. STATA software is used for statistical analyses.
Possible Results: The investigators can answer that the between-group differences in heart rate variability, cardio-ankle vascular index, ankle-brachial pressure index, psychosomatic distress, personality trait, family support and clinical outcomes between the mirabegron and the solifenacin groups. The above conclusions should be important for pre-treatment consultation.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 20 Years 至 99 Years(Adult, Older Adult)
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •Women with overactive bladder syndrome
- •≥20 year-old
排除标准
- •Urine retention,
- •acute angle glaucoma,
- •myasthenia gravis,
- •ulcerative colitis,
- •megacolon
研究组 & 干预措施
Solifenacin
Women with overactive bladder syndrome will be treated by solifenacin 5 mg qd * 12 weeks
干预措施: solifenacin (Drug)
Mirabegron
Women with overactive bladder syndrome will be treated by mirabegron 25 mg qd * 12 weeks
干预措施: mirabegron (Drug)
结局指标
主要结局
Between-group difference of the effect of drug on heart rate variability
时间窗: 12 weeks
Between-group difference of the effect of drug on heart rate variability, such as low frequency and high frequency
Between-group difference of the effect of drug on psychosomatic distress
时间窗: 12 weeks
Between-group difference of the effect of drug on psychosomatic distress by Brief Symptom Rating Scale
次要结局
- Between-group difference of the effect of drug on arterial stiffness(12 weeks)
- Between-group difference of the effect of drug on clinical efficacy(12 weeks)
